Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
Study Details
Study Description
Brief Summary
This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in treating patients with localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy without atezolizumab.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
PRIMARY OBJECTIVE:
- To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).
SECONDARY OBJECTIVES:
-
To compare overall survival between the two arms. II. To compare modified bladder intact event-free survival including cancer related death between arms.
-
To compare complete and partial pathologic response between arms at 3 months after completing chemoradiation therapy.
-
To estimate metastases-free survival by arm. V. To compare the qualitative and quantitative adverse events from each arm. VI. To estimate the rate of non-muscle invasive bladder cancer recurrence by arm.
-
To estimate the rate of salvage cystectomy and reasons for cystectomy by arm.
-
To compare mean patient-reported global quality of life (QOL) at week 54 using the European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ)-Core (C)30 Global Health Status (GHS) subscale score between patients with localized muscle-invasive bladder cancer randomized to chemoradiation with versus (vs.) without atezolizumab.
TRANSLATIONAL MEDICINE OBJECTIVES:
-
To test the hypothesis that a panel of validated biomarkers of concurrent CRT involving nuclear MRE11, impaired deoxyribonucleic acid damage response (DDR) function and tumor subtyping will be prognostic for BI-EFS among patients receiving either concurrent CRT or chemoimmuno-radiotherapy (CIRT) of the primary tumor.
-
To test the hypothesis that tumor total mutation burden, neoantigen burden, infiltrating immune response, PD-L1 expression and T cell response are associated with augmented response after concurrent CIRT.
-
To bank urine specimens for future use.
PATIENT-REPORTED OUTCOMES (PROs) OBJECTIVES:
- To compare mean patient-reported global QOL as measured by the EORTC QLQ-C30 Global Health Status subscale scores at week 54 between patients with localized muscle-invasive bladder cancer randomized to chemoradiation with versus without atezolizumab. (Primary) II. To compare mean patient-reported bowel symptoms at each assessment time by arm using the Expanded Prostate Cancer Index Composite (EPIC) Bowel Assessment from the Expanded Prostate Index, the bladder-specific supplement to the QLQ-C30, the EORTC QLQ-Muscle Invasive Bladder Cancer (BLM30), the Physical Functioning subscale of the EORTC QLQ-C30, and overall health status using the EuroQol Five Dimension Five Level Scale (EQ-5D-5L). (Exploratory) III. To compare longitudinal change over time by arm in patient-reported global QOL using the EORTC QLQ-C30, the Bowel Domain of the Expanded Prostate Index (EPIC Bowel Assessment), the bladder-specific supplement to the QLQ-C30, the EORTC QLQ-BLM30, the Physical Functioning subscale of the EORTC QLQ-C30, and overall health status using the EQ-5D-5L. (Exploratory)
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo radiation therapy (RT) (3 dimensional [D] CRT or intensity-modulated radiation therapy [IMRT]) daily Monday-Friday for up to 7-8 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine intravenously (IV) twice weekly for 6 weeks concurrent with RT, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity. Patients also undergo a transurethral resection of bladder tumor (TURBT) with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6 months through year 5 and computed tomography (CT) or magnetic resonance imaging (MRI) at randomization, at weeks 18, 30, 42, 54, then every 6months through year 2, followed by every 12 months through year 5.
ARM II: Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6 months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6months through year 2, followed by every 12 months through year 5.
After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 3 years.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Arm I (RT, chemotherapy) Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine IV twice weekly for 6 weeks concurrent with RT, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5. |
Procedure: Biopsy of Bladder
Undergo a bladder biopsy
Other Names:
Drug: Cisplatin
Given IV
Other Names:
Procedure: Computed Tomography
Undergo CT or MRI
Other Names:
Procedure: Cystoscopy
Undergo a cystoscopy
Drug: Fluorouracil
Given IV
Other Names:
Drug: Gemcitabine
Given IV
Other Names:
Procedure: Magnetic Resonance Imaging
Undergo CT or MRI
Other Names:
Drug: Mitomycin
Given IV
Other Names:
Other: Quality-of-Life Assessment
Ancillary studies
Other Names:
Radiation: Radiation Therapy
Undergo 3DCRT or IMRT
Other Names:
Other: Survey Administration
Ancillary studies
Procedure: Transurethral Resection of Bladder Tumor
Undergo a TURBT
Other Names:
|
| Experimental: Arm II (RT, chemotherapy, atezolizumab) Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5. |
Drug: Atezolizumab
Given IV
Other Names:
Procedure: Biopsy of Bladder
Undergo a bladder biopsy
Other Names:
Drug: Cisplatin
Given IV
Other Names:
Procedure: Computed Tomography
Undergo CT or MRI
Other Names:
Procedure: Cystoscopy
Undergo a cystoscopy
Drug: Fluorouracil
Given IV
Other Names:
Drug: Gemcitabine
Given IV
Other Names:
Procedure: Magnetic Resonance Imaging
Undergo CT or MRI
Other Names:
Drug: Mitomycin
Given IV
Other Names:
Other: Quality-of-Life Assessment
Ancillary studies
Other Names:
Radiation: Radiation Therapy
Undergo 3DCRT or IMRT
Other Names:
Other: Survey Administration
Ancillary studies
Procedure: Transurethral Resection of Bladder Tumor
Undergo a TURBT
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Bladder intact event-free survival (BI-EFS) [From the date of randomization to the first documentation of a BI-EFS event, assessed up to 5 years]
At each time point, futility will be evaluated, and in the latter two analyses, efficacy will also be evaluated as specified. The final BI-EFS intent-to-treat analysis will be conducted using a stratified logrank test stratifying on stratification factors, and testing treatment at the one-sided significance level of 0.022 to account for multiple interim testing. The hazard ratio (HR) will be estimated using a stratified Cox proportional hazards model and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median BI-EFS for each treatment arm.
Secondary Outcome Measures
- Overall survival (OS) [From date of randomization to death from any cause, assessed up to 5 years]
Will be estimated using Kaplan-Meier methodology for each treatment arm. Will be analyzed using a similar method as for BI-EFS.
- Modified bladder intact event-free survival (mBI-EFS) [From date of randomization to the first documentation of a mBI-EFS event, assessed within 90 days]
Analysis of modified BI-EFS, i.e., a sensitivity analysis of BI-EFS, where bladder cancer event is defined as histologically proven presence of muscle invasive bladder cancer, clinical evidence of nodal or metastatic disease, radical cystectomy, or death within 90 days of receiving protocol specified treatment, will also be conducted.
- Biopsy response [At 18 weeks]
The Cochran-Mantel-Haenszel statistic will be used with modified ridit scores to evaluate the biopsy outcomes of complete response versus (vs.) down-staging vs. no response for the two treatment arms.
- Complete response duration [From the date of the biopsy documenting the complete response to the time of muscle invasive recurrence, local progression, evidence of metastatic disease or death due to any cause, assessed at 18 weeks]
For the subset of patients who achieve a complete response during the week 18 biopsy window, complete response duration is defined from the date of the biopsy documenting the complete response to the time of muscle invasive recurrence, local progression, evidence of metastatic disease or death due to any cause. Will be analyzed using a similar method as for BI-EFS.
- Progression-free survival [From date of randomization to first radiologic or histologic evidence of local progression, nodal or distant metastasis, or death due to any cause, assessed up to 5 years]
Will be estimated using Kaplan-Meier methodology for each treatment arm. Will be analyzed using a similar method as for BI-EFS.
- Metastasis-free survival [From date of randomization to first radiologic or histologic evidence of metastatic disease or death due to any cause, assessed up to 5 years]
Will be estimated using Kaplan-Meier methodology for each treatment arm. Will be analyzed using a similar method as for BI-EFS.
- Cancer-specific survival [From date of randomization to date of death due to bladder cancer, assessed up to 5 years]
- Quality of life [Baseline up to 5 years]
Assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ)-C30. Will be examined using linear mixed models with patient considered as the random effect. The baseline physical function score and the stratification factors will be included in the regression model as adjustment covariates.
Other Outcome Measures
- Treatment interactions [Up to 5 years]
A Cox regression model will be used to evaluate the main effects of treatment arm and the main effect for each stratification factor and the interaction of the stratification factor with treatment in terms of both the primary endpoint and secondary endpoints. The stratification factors to be evaluated include: (1) clinical stage T2 vs. T3/T4a, (2) intended chemotherapy regimen cisplatin vs. 5-FU + mitomycin-C vs. gemcitabine, (3) radiation field small pelvis vs. bladder only and (4) performance status 0-1 vs. 2. There may be other radiation summary measures that may also be explored in terms of their modification of the experimental treatment effect including extent of radiation to lymph node fields. Subgroup analysis defined by stratification factors will also be conducted for primary endpoint and key secondary.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
STEP 1 REGISTRATION: If this will be the first patient from a registering site to receive a given RT modality (3DCRT vs. IMRT), the site must first submit pre-RT planning documents within 3 days of Step 1 registration and receive approval from Imaging and Radiation Oncology Core (IROC) before randomizing the patient to Step 2. If this will not be the first patient to receive a specific RT modality, the patient should be immediately randomized to Step 2 on the same day.
-
STEP 2 RANDOMIZATION: If patient required review of pre-RT planning, randomization must occur within 14 days of initial registration.
-
Patients must have histologically proven, T2-T4a N0M0 urothelial carcinoma of the bladder within 120 days prior to randomization and no intervening treatment between the histologic proof and randomization. Patients with mixed urothelial carcinoma will be eligible for the trial, but the presence of small cell carcinoma will make a patient ineligible. Patients with lymph nodes >= 1.0 cm in shortest cross-sectional diameter on imaging (computed tomography [CT]/magnetic resonance imaging [MRI] of abdomen and pelvis) must have a biopsy of the enlarged lymph node showing no tumor involvement within 70 days prior to randomization. These patients may be suitable for neoadjuvant chemotherapy and radical cystectomy and are eligible for this trial if they seek out a bladder sparing treatment strategy, however patients who have received prior systemic chemotherapy for bladder cancer are not eligible for the trial.
-
Patients must undergo a transurethral resection of bladder tumor (TURBT) within 70 days prior to randomization. In a situation where a patient is referred from outside to the enrolling institution, patient must have a repeat office cystoscopy by the urologist who will be following the patient on the clinical trial to assess the adequacy of the prior TURBT. This cystoscopy can be performed in urologist office without general anesthesia. Patient may then undergo repeat TURBT if deemed necessary as standard of care by the treating urologist. Patients may have either completely or partially resected tumors as long as the treating urologist attempted maximal resection. Patient must not have T4b disease
-
Patients must undergo radiological staging within 70 days prior to randomization. Imaging of chest, abdomen, and pelvis must be performed using CT or MRI. Patients must not have evidence of T4bN1-3 disease. Eligibility is based on the local radiology report.
-
Patients with hydronephrosis are eligible if they have unilateral hydronephrosis and kidney function meets criteria specified.
-
Patient must be planning to receive one of the protocol specified chemotherapy regimens.
-
All adverse events associated with any prior surgery and intravesical therapy must have resolved to Common Terminology Criteria for Adverse Events (CTCAE) grade =< 2 prior to randomization.
-
Patients must be >= 18 years of age
-
Patient may or may not be radical cystectomy candidates.
-
Absolute neutrophil count (ANC) >=1,500/microliter (mcL) (within 28 days prior to randomization).
-
Platelets >= 100,000/mcL (within 28 days prior to randomization).
-
Hemoglobin >= 9 g/dL (within 28 days prior to randomization).
-
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except patients with Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL) (within 28 days prior to randomization).
-
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x IULN (within 28 days prior to randomization).
-
Patients must have adequate renal function as evidenced by calculated creatinine clearance >= 25 mL/min. The creatinine used to calculate the clearance result must have been obtained within 28 days prior to randomization.
-
Patients must have Zubrod performance status =< 2.
-
Patients must have a baseline electrocardiography (ECG) performed within 30 days prior to randomization.
-
If patient has a known history of hepatitis B virus (HBV) or hepatitis C virus (HCV), they must meet the following criteria within 28 days prior to randomization.
-
Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible.
-
Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
-
Patients who are known to be positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:
-
A stable regimen of highly active anti-retroviral therapy (HAART)
-
No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
-
A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests within 28 days prior to randomization.
-
Female patients of childbearing potential must have a serum pregnancy test prior to randomization. Patients must not be pregnant or nursing due to the potential teratogenic side effects of the protocol treatment. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of protocol treatment, and for 5 months (150 days) after the last dose of all study drugs. A woman is considered to be of "reproductive potential" if she has had a menses at any time in the preceding 12 consecutive months.
-
Patients must be offered the opportunity to participate in specimen banking for future studies.
-
Patients who can complete Patient-Reported Outcome instruments in English or Spanish must agree to complete the EORTC QLQ-C30, the EORTC QLQ-BLM30, the EPIC Bowel Assessment, and the EQ-5D-5L per protocol schedule of assessment.
-
As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
Exclusion Criteria:
-
Patients must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder within the previous 24 months except Ta/T1/carcinoma in situ (CIS) of the upper urinary tract including renal pelvis and ureter if the patient had undergone complete nephroureterectomy.
-
Patients must not have diffuse CIS based on cystoscopy and biopsy.
-
Patient must not have received any systemic chemotherapy for their bladder cancer.
-
Patient must not have had prior pelvic radiation.
-
Patients must not have received prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor.
-
Patients must not have received any systemic therapy (including, but not limited to, interferon alfa-2b, high dose IL-2, pegylated interferon [PEG-IFN], anti-PD-1, anti-PD-L1), for non-muscle invasive bladder cancer. Prior intravesical bacillus Calmette-Guerin (BCG), interferon, and intravesical chemotherapy are allowed.
-
Patients must not have received any of the following prohibited therapies within 28 days prior to randomization or be planning to receive any of the following prohibited therapies during protocol treatment:
-
Anti-cancer systemic chemotherapy or biological therapy not specified in the protocol.
-
Immunotherapy not specified in this protocol.
-
Systemic or intravesical use of any non-study anti-cancer agent (investigational or non-investigational).
-
Investigational agents other than atezolizumab.
-
Live vaccines: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated vaccines, and are not allowed. Prior administration of intravesical BCG is allowed.
-
Glucocorticoids for any purpose other than to modulate symptoms from an event of suspected immunologic etiology. The use of physiologic doses of corticosteroids (defined as 10 mg prednisone) are acceptable, however site investigators should consult with the study chair for any dose higher than 10 mg prednisone. Dexamethasone 4 mg IV with chemotherapy to prevent nausea is allowed.
-
RANKL infusion: Concurrent denosumab (which binds the cytokine RANKL) for any known indication is prohibited due to interaction with study medication.
-
Patients must not have a major surgical procedure within 28 days prior to randomization. If patient had any surgical procedure then they should have recovered to full presurgical performance status and surgical adverse events should have resolved to grade =< 2. TURBT is not considered a major surgical procedure.
-
Patients must not have received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization. Exceptions:
-
Patients may have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea).
-
The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed. Physiological doses equivalent of 10 mg prednisone daily are allowed. Short term steroids given as antiemetic therapy, e.g. 4 mg dexamethasone or equivalent once a week, is allowed.
-
Patients must not have received a live, attenuated vaccine within 4 weeks prior to randomization or anticipate that such a live, attenuated vaccine will be required while on protocol treatment and up to 5 months after the last dose of protocol treatment.
-
Inactivated influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to randomization or while on protocol treatment and up to 5 months after the last dose of protocol treatment.
-
Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation.
-
Patients must not have clinically significant liver disease that precludes patient from treatment regimens prescribed on the study (including, but not limited to, active viral, alcoholic or other autoimmune hepatitis, cirrhosis or inherited liver disease).
-
Patient must not have history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis.
-
Patients must not have an active infection requiring oral or IV antibiotics within 14 days prior to randomization. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are not eligible. If patient develops urinary tract infection after TURBT they must have recovered from the infection prior to registration.
-
Patients must not have active autoimmune disease that has required systemic treatment in past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, Graves' disease treated with methimazole or glomerulonephritis.
-
Patient must not have a history of active tuberculosis.
-
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for two years. Patients with localized prostate cancer who are being followed by an active surveillance program are also eligible.
-
Patients must not be known to be allergic to Chinese hamster egg or ovary cell products and must not have any known major allergic reactions to any study drug.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic Hospital in Arizona | Phoenix | Arizona | United States | 85054 |
| 2 | Mayo Clinic in Arizona | Scottsdale | Arizona | United States | 85259 |
| 3 | Banner University Medical Center - Tucson | Tucson | Arizona | United States | 85719 |
| 4 | University of Arizona Cancer Center-North Campus | Tucson | Arizona | United States | 85719 |
| 5 | Alta Bates Summit Medical Center-Herrick Campus | Berkeley | California | United States | 94704 |
| 6 | UC San Diego Moores Cancer Center | La Jolla | California | United States | 92093 |
| 7 | Los Angeles County-USC Medical Center | Los Angeles | California | United States | 90033 |
| 8 | USC / Norris Comprehensive Cancer Center | Los Angeles | California | United States | 90033 |
| 9 | Cedars Sinai Medical Center | Los Angeles | California | United States | 90048 |
| 10 | Fremont - Rideout Cancer Center | Marysville | California | United States | 95901 |
| 11 | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange | California | United States | 92868 |
| 12 | Palo Alto Medical Foundation Health Care | Palo Alto | California | United States | 94301 |
| 13 | Sutter Roseville Medical Center | Roseville | California | United States | 95661 |
| 14 | Sutter Medical Center Sacramento | Sacramento | California | United States | 95816 |
| 15 | University of California Davis Comprehensive Cancer Center | Sacramento | California | United States | 95817 |
| 16 | Pacific Central Coast Health Center-San Luis Obispo | San Luis Obispo | California | United States | 93401 |
| 17 | University of Colorado Hospital | Aurora | Colorado | United States | 80045 |
| 18 | Rocky Mountain Cancer Centers-Boulder | Boulder | Colorado | United States | 80304 |
| 19 | UCHealth Memorial Hospital Central | Colorado Springs | Colorado | United States | 80909 |
| 20 | Memorial Hospital North | Colorado Springs | Colorado | United States | 80920 |
| 21 | Shaw Cancer Center | Edwards | Colorado | United States | 81632 |
| 22 | Poudre Valley Hospital | Fort Collins | Colorado | United States | 80524 |
| 23 | Cancer Care and Hematology-Fort Collins | Fort Collins | Colorado | United States | 80528 |
| 24 | UCHealth Greeley Hospital | Greeley | Colorado | United States | 80631 |
| 25 | Medical Center of the Rockies | Loveland | Colorado | United States | 80538 |
| 26 | Smilow Cancer Hospital Care Center - Guiford | Guilford | Connecticut | United States | 06437 |
| 27 | Hartford Hospital | Hartford | Connecticut | United States | 06102 |
| 28 | Midstate Medical Center | Meriden | Connecticut | United States | 06451 |
| 29 | The Hospital of Central Connecticut | New Britain | Connecticut | United States | 06050 |
| 30 | Yale University | New Haven | Connecticut | United States | 06520 |
| 31 | Smilow Cancer Hospital Care Center-Trumbull | Trumbull | Connecticut | United States | 06611 |
| 32 | Beebe South Coastal Health Campus | Frankford | Delaware | United States | 19945 |
| 33 | Helen F Graham Cancer Center | Newark | Delaware | United States | 19713 |
| 34 | Medical Oncology Hematology Consultants PA | Newark | Delaware | United States | 19713 |
| 35 | Beebe Health Campus | Rehoboth Beach | Delaware | United States | 19971 |
| 36 | Sibley Memorial Hospital | Washington | District of Columbia | United States | 20016 |
| 37 | Mount Sinai Comprehensive Cancer Center at Aventura | Aventura | Florida | United States | 33180 |
| 38 | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables | Florida | United States | 33146 |
| 39 | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach | Florida | United States | 33442 |
| 40 | University of Florida Health Science Center - Gainesville | Gainesville | Florida | United States | 32610 |
| 41 | Mount Sinai Medical Center | Miami Beach | Florida | United States | 33140 |
| 42 | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami | Florida | United States | 33136 |
| 43 | Moffitt Cancer Center | Tampa | Florida | United States | 33612 |
| 44 | Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia | United States | 30322 |
| 45 | Emory Saint Joseph's Hospital | Atlanta | Georgia | United States | 30342 |
| 46 | CTCA at Southeastern Regional Medical Center | Newnan | Georgia | United States | 30265 |
| 47 | Hawaii Cancer Care - Savio | 'Aiea | Hawaii | United States | 96701 |
| 48 | Pali Momi Medical Center | 'Aiea | Hawaii | United States | 96701 |
| 49 | The Cancer Center of Hawaii-Pali Momi | 'Aiea | Hawaii | United States | 96701 |
| 50 | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu | Hawaii | United States | 96813 |
| 51 | Queen's Cancer Cenrer - POB I | Honolulu | Hawaii | United States | 96813 |
| 52 | Queen's Medical Center | Honolulu | Hawaii | United States | 96813 |
| 53 | Straub Clinic and Hospital | Honolulu | Hawaii | United States | 96813 |
| 54 | Queen's Cancer Center - Kuakini | Honolulu | Hawaii | United States | 96817 |
| 55 | The Cancer Center of Hawaii-Liliha | Honolulu | Hawaii | United States | 96817 |
| 56 | Illinois CancerCare-Bloomington | Bloomington | Illinois | United States | 61704 |
| 57 | Illinois CancerCare-Canton | Canton | Illinois | United States | 61520 |
| 58 | Illinois CancerCare-Carthage | Carthage | Illinois | United States | 62321 |
| 59 | Northwestern University | Chicago | Illinois | United States | 60611 |
| 60 | Rush University Medical Center | Chicago | Illinois | United States | 60612 |
| 61 | Decatur Memorial Hospital | Decatur | Illinois | United States | 62526 |
| 62 | Northwestern Medicine Cancer Center Kishwaukee | DeKalb | Illinois | United States | 60115 |
| 63 | Crossroads Cancer Center | Effingham | Illinois | United States | 62401 |
| 64 | Elmhurst Memorial Hospital | Elmhurst | Illinois | United States | 60126 |
| 65 | Illinois CancerCare-Eureka | Eureka | Illinois | United States | 61530 |
| 66 | Illinois CancerCare-Galesburg | Galesburg | Illinois | United States | 61401 |
| 67 | Western Illinois Cancer Treatment Center | Galesburg | Illinois | United States | 61401 |
| 68 | Northwestern Medicine Cancer Center Delnor | Geneva | Illinois | United States | 60134 |
| 69 | Edward Hines Jr VA Hospital | Hines | Illinois | United States | 60141 |
| 70 | Illinois CancerCare-Kewanee Clinic | Kewanee | Illinois | United States | 61443 |
| 71 | Illinois CancerCare-Macomb | Macomb | Illinois | United States | 61455 |
| 72 | Loyola University Medical Center | Maywood | Illinois | United States | 60153 |
| 73 | Edward Hospital/Cancer Center | Naperville | Illinois | United States | 60540 |
| 74 | Illinois CancerCare-Ottawa Clinic | Ottawa | Illinois | United States | 61350 |
| 75 | Illinois CancerCare-Pekin | Pekin | Illinois | United States | 61554 |
| 76 | Illinois CancerCare-Peoria | Peoria | Illinois | United States | 61615 |
| 77 | Methodist Medical Center of Illinois | Peoria | Illinois | United States | 61636 |
| 78 | OSF Saint Francis Medical Center | Peoria | Illinois | United States | 61637 |
| 79 | Illinois CancerCare-Peru | Peru | Illinois | United States | 61354 |
| 80 | Illinois CancerCare-Princeton | Princeton | Illinois | United States | 61356 |
| 81 | Springfield Clinic | Springfield | Illinois | United States | 62702 |
| 82 | Memorial Medical Center | Springfield | Illinois | United States | 62781 |
| 83 | Carle Cancer Center | Urbana | Illinois | United States | 61801 |
| 84 | Northwestern Medicine Cancer Center Warrenville | Warrenville | Illinois | United States | 60555 |
| 85 | Illinois CancerCare - Washington | Washington | Illinois | United States | 61571 |
| 86 | Community Cancer Center East | Indianapolis | Indiana | United States | 46219 |
| 87 | Community Cancer Center South | Indianapolis | Indiana | United States | 46227 |
| 88 | Community Cancer Center North | Indianapolis | Indiana | United States | 46256 |
| 89 | Reid Health | Richmond | Indiana | United States | 47374 |
| 90 | Mary Greeley Medical Center | Ames | Iowa | United States | 50010 |
| 91 | McFarland Clinic PC - Ames | Ames | Iowa | United States | 50010 |
| 92 | Medical Oncology and Hematology Associates-West Des Moines | Clive | Iowa | United States | 50325 |
| 93 | Mercy Cancer Center-West Lakes | Clive | Iowa | United States | 50325 |
| 94 | Greater Regional Medical Center | Creston | Iowa | United States | 50801 |
| 95 | Iowa Methodist Medical Center | Des Moines | Iowa | United States | 50309 |
| 96 | Medical Oncology and Hematology Associates-Laurel | Des Moines | Iowa | United States | 50314 |
| 97 | Mercy Medical Center - Des Moines | Des Moines | Iowa | United States | 50314 |
| 98 | Mercy Medical Center-West Lakes | West Des Moines | Iowa | United States | 50266 |
| 99 | University of Kansas Cancer Center | Kansas City | Kansas | United States | 66160 |
| 100 | University of Kansas Cancer Center-Overland Park | Overland Park | Kansas | United States | 66210 |
| 101 | University of Kansas Hospital-Westwood Cancer Center | Westwood | Kansas | United States | 66205 |
| 102 | Ascension Via Christi Hospitals Wichita | Wichita | Kansas | United States | 67214 |
| 103 | Baptist Health Lexington | Lexington | Kentucky | United States | 40503 |
| 104 | University of Kentucky/Markey Cancer Center | Lexington | Kentucky | United States | 40536 |
| 105 | The James Graham Brown Cancer Center at University of Louisville | Louisville | Kentucky | United States | 40202 |
| 106 | Baptist Health Louisville | Louisville | Kentucky | United States | 40207 |
| 107 | East Jefferson General Hospital | Metairie | Louisiana | United States | 70006 |
| 108 | LSU Healthcare Network / Metairie Multi-Specialty Clinic | Metairie | Louisiana | United States | 70006 |
| 109 | MaineHealth Coastal Cancer Treatment Center | Bath | Maine | United States | 04530 |
| 110 | Waldo County General Hospital | Belfast | Maine | United States | 04915 |
| 111 | MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford | Biddeford | Maine | United States | 04005 |
| 112 | Stephens Memorial Hospital | Norway | Maine | United States | 04268 |
| 113 | Maine Medical Center-Bramhall Campus | Portland | Maine | United States | 04102 |
| 114 | Penobscot Bay Medical Center | Rockport | Maine | United States | 04856 |
| 115 | MaineHealth Cancer Care Center of York County | Sanford | Maine | United States | 04073 |
| 116 | MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford | Sanford | Maine | United States | 04073 |
| 117 | Maine Medical Center- Scarborough Campus | Scarborough | Maine | United States | 04074 |
| 118 | Maine Medical Partners - South Portland | South Portland | Maine | United States | 04106 |
| 119 | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | United States | 21287 |
| 120 | Massachusetts General Hospital Cancer Center | Boston | Massachusetts | United States | 02114 |
| 121 | Dana-Farber Cancer Institute | Boston | Massachusetts | United States | 02215 |
| 122 | Lowell General Hospital | Lowell | Massachusetts | United States | 01854 |
| 123 | Saint Joseph Mercy Hospital | Ann Arbor | Michigan | United States | 48106 |
| 124 | University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | United States | 48109 |
| 125 | Bronson Battle Creek | Battle Creek | Michigan | United States | 49017 |
| 126 | Saint Joseph Mercy Brighton | Brighton | Michigan | United States | 48114 |
| 127 | University of Michigan - Brighton Center for Specialty Care | Brighton | Michigan | United States | 48116 |
| 128 | Saint Joseph Mercy Canton | Canton | Michigan | United States | 48188 |
| 129 | Saint Joseph Mercy Chelsea | Chelsea | Michigan | United States | 48118 |
| 130 | GenesisCare USA - Clarkston | Clarkston | Michigan | United States | 48346 |
| 131 | Beaumont Hospital - Dearborn | Dearborn | Michigan | United States | 48124 |
| 132 | Wayne State University/Karmanos Cancer Institute | Detroit | Michigan | United States | 48201 |
| 133 | Henry Ford Hospital | Detroit | Michigan | United States | 48202 |
| 134 | Ascension Saint John Hospital | Detroit | Michigan | United States | 48236 |
| 135 | GenesisCare USA - Farmington Hills | Farmington Hills | Michigan | United States | 48334 |
| 136 | Weisberg Cancer Treatment Center | Farmington Hills | Michigan | United States | 48334 |
| 137 | Beaumont Hospital - Farmington Hills | Farmington Hills | Michigan | United States | 48336 |
| 138 | West Michigan Cancer Center | Kalamazoo | Michigan | United States | 49007 |
| 139 | Sparrow Hospital | Lansing | Michigan | United States | 48912 |
| 140 | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia | Michigan | United States | 48154 |
| 141 | GenesisCare USA - Madison Heights | Madison Heights | Michigan | United States | 48071 |
| 142 | 21st Century Oncology-Pontiac | Pontiac | Michigan | United States | 48341 |
| 143 | William Beaumont Hospital-Royal Oak | Royal Oak | Michigan | United States | 48073 |
| 144 | Ascension Saint Mary's Hospital | Saginaw | Michigan | United States | 48601 |
| 145 | Munson Medical Center | Traverse City | Michigan | United States | 49684 |
| 146 | William Beaumont Hospital - Troy | Troy | Michigan | United States | 48085 |
| 147 | GenesisCare USA - Troy | Troy | Michigan | United States | 48098 |
| 148 | Saint John Macomb-Oakland Hospital | Warren | Michigan | United States | 48093 |
| 149 | Henry Ford West Bloomfield Hospital | West Bloomfield | Michigan | United States | 48322 |
| 150 | Metro Health Hospital | Wyoming | Michigan | United States | 49519 |
| 151 | Sanford Joe Lueken Cancer Center | Bemidji | Minnesota | United States | 56601 |
| 152 | Mercy Hospital | Coon Rapids | Minnesota | United States | 55433 |
| 153 | Miller-Dwan Hospital | Duluth | Minnesota | United States | 55805 |
| 154 | Fairview Southdale Hospital | Edina | Minnesota | United States | 55435 |
| 155 | Unity Hospital | Fridley | Minnesota | United States | 55432 |
| 156 | Monticello Cancer Center | Monticello | Minnesota | United States | 55362 |
| 157 | Mayo Clinic in Rochester | Rochester | Minnesota | United States | 55905 |
| 158 | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud | Minnesota | United States | 56303 |
| 159 | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park | Minnesota | United States | 55416 |
| 160 | Regions Hospital | Saint Paul | Minnesota | United States | 55101 |
| 161 | Parkland Health Center-Bonne Terre | Bonne Terre | Missouri | United States | 63628 |
| 162 | Saint Francis Medical Center | Cape Girardeau | Missouri | United States | 63703 |
| 163 | Siteman Cancer Center at West County Hospital | Creve Coeur | Missouri | United States | 63141 |
| 164 | University of Kansas Cancer Center - North | Kansas City | Missouri | United States | 64154 |
| 165 | University of Kansas Cancer Center - Lee's Summit | Lee's Summit | Missouri | United States | 64064 |
| 166 | Heartland Regional Medical Center | Saint Joseph | Missouri | United States | 64506 |
| 167 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63110 |
| 168 | Siteman Cancer Center-South County | Saint Louis | Missouri | United States | 63129 |
| 169 | Missouri Baptist Medical Center | Saint Louis | Missouri | United States | 63131 |
| 170 | Mercy Hospital Saint Louis | Saint Louis | Missouri | United States | 63141 |
| 171 | Siteman Cancer Center at Saint Peters Hospital | Saint Peters | Missouri | United States | 63376 |
| 172 | Sainte Genevieve County Memorial Hospital | Sainte Genevieve | Missouri | United States | 63670 |
| 173 | CoxHealth South Hospital | Springfield | Missouri | United States | 65807 |
| 174 | Missouri Baptist Sullivan Hospital | Sullivan | Missouri | United States | 63080 |
| 175 | Missouri Baptist Outpatient Center-Sunset Hills | Sunset Hills | Missouri | United States | 63127 |
| 176 | Bozeman Deaconess Hospital | Bozeman | Montana | United States | 59715 |
| 177 | Benefis Healthcare- Sletten Cancer Institute | Great Falls | Montana | United States | 59405 |
| 178 | Nebraska Medicine-Bellevue | Bellevue | Nebraska | United States | 68123 |
| 179 | CHI Health Good Samaritan | Kearney | Nebraska | United States | 68847 |
| 180 | Nebraska Methodist Hospital | Omaha | Nebraska | United States | 68114 |
| 181 | Nebraska Medicine-Village Pointe | Omaha | Nebraska | United States | 68118 |
| 182 | University of Nebraska Medical Center | Omaha | Nebraska | United States | 68198 |
| 183 | OptumCare Cancer Care at Charleston | Las Vegas | Nevada | United States | 89102 |
| 184 | Radiation Oncology Centers of Nevada Central | Las Vegas | Nevada | United States | 89106 |
| 185 | Comprehensive Cancer Centers of Nevada - Northwest | Las Vegas | Nevada | United States | 89128 |
| 186 | Comprehensive Cancer Centers of Nevada - Town Center | Las Vegas | Nevada | United States | 89144 |
| 187 | Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | United States | 89148 |
| 188 | OptumCare Cancer Care at Fort Apache | Las Vegas | Nevada | United States | 89148 |
| 189 | Comprehensive Cancer Centers of Nevada - Central Valley | Las Vegas | Nevada | United States | 89169 |
| 190 | Renown Regional Medical Center | Reno | Nevada | United States | 89502 |
| 191 | Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | United States | 03756 |
| 192 | Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | United States | 07920 |
| 193 | Cooper Hospital University Medical Center | Camden | New Jersey | United States | 08103 |
| 194 | Hackensack University Medical Center | Hackensack | New Jersey | United States | 07601 |
| 195 | Memorial Sloan Kettering Monmouth | Middletown | New Jersey | United States | 07748 |
| 196 | Memorial Sloan Kettering Bergen | Montvale | New Jersey | United States | 07645 |
| 197 | MD Anderson Cancer Center at Cooper-Voorhees | Voorhees | New Jersey | United States | 08043 |
| 198 | Montefiore Medical Center-Einstein Campus | Bronx | New York | United States | 10461 |
| 199 | Montefiore Medical Center-Weiler Hospital | Bronx | New York | United States | 10461 |
| 200 | Montefiore Medical Center - Moses Campus | Bronx | New York | United States | 10467 |
| 201 | Memorial Sloan Kettering Commack | Commack | New York | United States | 11725 |
| 202 | Memorial Sloan Kettering Westchester | Harrison | New York | United States | 10604 |
| 203 | Northwell Health/Center for Advanced Medicine | Lake Success | New York | United States | 11042 |
| 204 | Memorial Sloan Kettering Cancer Center | New York | New York | United States | 10065 |
| 205 | Highland Hospital | Rochester | New York | United States | 14620 |
| 206 | University of Rochester | Rochester | New York | United States | 14642 |
| 207 | Phelps Memorial Hospital Center | Sleepy Hollow | New York | United States | 10591 |
| 208 | Stony Brook University Medical Center | Stony Brook | New York | United States | 11794 |
| 209 | State University of New York Upstate Medical University | Syracuse | New York | United States | 13210 |
| 210 | Memorial Sloan Kettering Nassau | Uniondale | New York | United States | 11553 |
| 211 | Good Samaritan Hospital Medical Center | West Islip | New York | United States | 11795 |
| 212 | Margaret R Pardee Memorial Hospital | Hendersonville | North Carolina | United States | 28791 |
| 213 | Vidant Oncology-Kenansville | Kenansville | North Carolina | United States | 28349 |
| 214 | Vidant Oncology-Kinston | Kinston | North Carolina | United States | 28501 |
| 215 | Vidant Oncology-Richlands | Richlands | North Carolina | United States | 28574 |
| 216 | Sanford Bismarck Medical Center | Bismarck | North Dakota | United States | 58501 |
| 217 | Sanford Broadway Medical Center | Fargo | North Dakota | United States | 58122 |
| 218 | Sanford Roger Maris Cancer Center | Fargo | North Dakota | United States | 58122 |
| 219 | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati | Ohio | United States | 45219 |
| 220 | MetroHealth Medical Center | Cleveland | Ohio | United States | 44109 |
| 221 | Ohio State University Comprehensive Cancer Center | Columbus | Ohio | United States | 43210 |
| 222 | Dayton Physician LLC-Miami Valley Hospital North | Dayton | Ohio | United States | 45415 |
| 223 | Greater Dayton Cancer Center | Kettering | Ohio | United States | 45409 |
| 224 | Kettering Medical Center | Kettering | Ohio | United States | 45429 |
| 225 | University of Cincinnati Cancer Center-West Chester | West Chester | Ohio | United States | 45069 |
| 226 | Cancer Centers of Southwest Oklahoma Research | Lawton | Oklahoma | United States | 73505 |
| 227 | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | United States | 73104 |
| 228 | Oregon Health and Science University | Portland | Oregon | United States | 97239 |
| 229 | Lehigh Valley Hospital-Cedar Crest | Allentown | Pennsylvania | United States | 18103 |
| 230 | UPMC Altoona | Altoona | Pennsylvania | United States | 16601 |
| 231 | UPMC-Heritage Valley Health System Beaver | Beaver | Pennsylvania | United States | 15009 |
| 232 | Lehigh Valley Hospital - Muhlenberg | Bethlehem | Pennsylvania | United States | 18017 |
| 233 | Carlisle Regional Cancer Center | Carlisle | Pennsylvania | United States | 17015 |
| 234 | Christiana Care Health System-Concord Health Center | Chadds Ford | Pennsylvania | United States | 19317 |
| 235 | Geisinger Medical Center | Danville | Pennsylvania | United States | 17822 |
| 236 | UPMC Hillman Cancer Center Erie | Erie | Pennsylvania | United States | 16505 |
| 237 | UPMC Cancer Center at UPMC Horizon | Farrell | Pennsylvania | United States | 16121 |
| 238 | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg | Pennsylvania | United States | 15601 |
| 239 | UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg | Pennsylvania | United States | 17109 |
| 240 | Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania | United States | 17033-0850 |
| 241 | UPMC-Johnstown/John P. Murtha Regional Cancer Center | Johnstown | Pennsylvania | United States | 15901 |
| 242 | Geisinger Medical Oncology-Lewisburg | Lewisburg | Pennsylvania | United States | 17837 |
| 243 | UPMC Cancer Center at UPMC McKeesport | McKeesport | Pennsylvania | United States | 15132 |
| 244 | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg | Pennsylvania | United States | 17050 |
| 245 | UPMC Cancer Center - Monroeville | Monroeville | Pennsylvania | United States | 15146 |
| 246 | UPMC-Coraopolis/Heritage Valley Radiation Oncology | Moon | Pennsylvania | United States | 15108 |
| 247 | UPMC-Magee Womens Hospital | Pittsburgh | Pennsylvania | United States | 15213 |
| 248 | UPMC-Saint Margaret | Pittsburgh | Pennsylvania | United States | 15215 |
| 249 | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania | United States | 15232 |
| 250 | UPMC-Shadyside Hospital | Pittsburgh | Pennsylvania | United States | 15232 |
| 251 | UPMC-Passavant Hospital | Pittsburgh | Pennsylvania | United States | 15237 |
| 252 | UPMC-Saint Clair Hospital Cancer Center | Pittsburgh | Pennsylvania | United States | 15243 |
| 253 | UPMC Cancer Center at UPMC Northwest | Seneca | Pennsylvania | United States | 16346 |
| 254 | UPMC Uniontown Hospital Radiation Oncology | Uniontown | Pennsylvania | United States | 15401 |
| 255 | UPMC Washington Hospital Radiation Oncology | Washington | Pennsylvania | United States | 15301 |
| 256 | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre | Pennsylvania | United States | 18711 |
| 257 | UPMC Memorial | York | Pennsylvania | United States | 17408 |
| 258 | Medical University of South Carolina | Charleston | South Carolina | United States | 29425 |
| 259 | Prisma Health Cancer Institute - Faris | Greenville | South Carolina | United States | 29605 |
| 260 | Prisma Health Cancer Institute - Eastside | Greenville | South Carolina | United States | 29615 |
| 261 | Prisma Health Cancer Institute - Greer | Greer | South Carolina | United States | 29650 |
| 262 | Carolina Regional Cancer Center | Myrtle Beach | South Carolina | United States | 29577 |
| 263 | Spartanburg Medical Center | Spartanburg | South Carolina | United States | 29303 |
| 264 | Sanford Cancer Center Oncology Clinic | Sioux Falls | South Dakota | United States | 57104 |
| 265 | Sanford USD Medical Center - Sioux Falls | Sioux Falls | South Dakota | United States | 57117-5134 |
| 266 | Vanderbilt University/Ingram Cancer Center | Nashville | Tennessee | United States | 37232 |
| 267 | UT Southwestern/Simmons Cancer Center-Dallas | Dallas | Texas | United States | 75390 |
| 268 | University of Texas Medical Branch | Galveston | Texas | United States | 77555-0565 |
| 269 | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston | Texas | United States | 77030 |
| 270 | Michael E DeBakey VA Medical Center | Houston | Texas | United States | 77030 |
| 271 | UT Southwestern Clinical Center at Richardson/Plano | Richardson | Texas | United States | 75080 |
| 272 | Augusta Health Center for Cancer and Blood Disorders | Fishersville | Virginia | United States | 22939 |
| 273 | MultiCare Auburn Medical Center | Auburn | Washington | United States | 98001 |
| 274 | Harrison HealthPartners Hematology and Oncology-Bremerton | Bremerton | Washington | United States | 98310 |
| 275 | Harrison Medical Center | Bremerton | Washington | United States | 98310 |
| 276 | MultiCare Gig Harbor Medical Park | Gig Harbor | Washington | United States | 98335 |
| 277 | Seattle Cancer Care Alliance at EvergreenHealth | Kirkland | Washington | United States | 98034 |
| 278 | MultiCare Good Samaritan Hospital | Puyallup | Washington | United States | 98372 |
| 279 | Seattle Cancer Care Alliance | Seattle | Washington | United States | 98109 |
| 280 | University of Washington Medical Center - Montlake | Seattle | Washington | United States | 98195 |
| 281 | MultiCare Tacoma General Hospital | Tacoma | Washington | United States | 98405 |
| 282 | West Virginia University Healthcare | Morgantown | West Virginia | United States | 26506 |
| 283 | Langlade Hospital and Cancer Center | Antigo | Wisconsin | United States | 54409 |
| 284 | Ascension Saint Elizabeth Hospital | Appleton | Wisconsin | United States | 54915 |
| 285 | Northwest Wisconsin Cancer Center | Ashland | Wisconsin | United States | 54806 |
| 286 | Aurora Cancer Care-Southern Lakes VLCC | Burlington | Wisconsin | United States | 53105 |
| 287 | Marshfield Medical Center-EC Cancer Center | Eau Claire | Wisconsin | United States | 54701 |
| 288 | Mayo Clinic Health System-Eau Claire Clinic | Eau Claire | Wisconsin | United States | 54701 |
| 289 | Aurora Health Care Germantown Health Center | Germantown | Wisconsin | United States | 53022 |
| 290 | Aurora Cancer Care-Grafton | Grafton | Wisconsin | United States | 53024 |
| 291 | Bellin Memorial Hospital | Green Bay | Wisconsin | United States | 54301 |
| 292 | Aurora BayCare Medical Center | Green Bay | Wisconsin | United States | 54311 |
| 293 | Aurora Cancer Care-Kenosha South | Kenosha | Wisconsin | United States | 53142 |
| 294 | Mayo Clinic Health System-Franciscan Healthcare | La Crosse | Wisconsin | United States | 54601 |
| 295 | Aurora Bay Area Medical Group-Marinette | Marinette | Wisconsin | United States | 54143 |
| 296 | Marshfield Medical Center-Marshfield | Marshfield | Wisconsin | United States | 54449 |
| 297 | Aspirus Medford Hospital | Medford | Wisconsin | United States | 54451 |
| 298 | Aurora Cancer Care-Milwaukee | Milwaukee | Wisconsin | United States | 53209 |
| 299 | Aurora Saint Luke's Medical Center | Milwaukee | Wisconsin | United States | 53215 |
| 300 | Aurora Sinai Medical Center | Milwaukee | Wisconsin | United States | 53233 |
| 301 | Marshfield Clinic-Minocqua Center | Minocqua | Wisconsin | United States | 54548 |
| 302 | Cancer Center of Western Wisconsin | New Richmond | Wisconsin | United States | 54017 |
| 303 | Ascension Mercy Hospital | Oshkosh | Wisconsin | United States | 54904 |
| 304 | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh | Wisconsin | United States | 54904 |
| 305 | Ascension All Saints Hospital | Racine | Wisconsin | United States | 53405 |
| 306 | Aurora Cancer Care-Racine | Racine | Wisconsin | United States | 53406 |
| 307 | Marshfield Medical Center-Rice Lake | Rice Lake | Wisconsin | United States | 54868 |
| 308 | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan | Wisconsin | United States | 53081 |
| 309 | Marshfield Medical Center-River Region at Stevens Point | Stevens Point | Wisconsin | United States | 54482 |
| 310 | Aurora Medical Center in Summit | Summit | Wisconsin | United States | 53066 |
| 311 | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers | Wisconsin | United States | 54241 |
| 312 | Aspirus Regional Cancer Center | Wausau | Wisconsin | United States | 54401 |
| 313 | Aurora Cancer Care-Milwaukee West | Wauwatosa | Wisconsin | United States | 53226 |
| 314 | Aurora West Allis Medical Center | West Allis | Wisconsin | United States | 53227 |
| 315 | Diagnostic and Treatment Center | Weston | Wisconsin | United States | 54476 |
| 316 | Marshfield Medical Center - Weston | Weston | Wisconsin | United States | 54476 |
| 317 | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids | Wisconsin | United States | 54494 |
Sponsors and Collaborators
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Parminder Singh, Southwest Oncology Group
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NCI-2018-03264
- NCI-2018-03264
- S1806
- S1806
- U10CA180888